<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00795821</url>
  </required_header>
  <id_info>
    <org_study_id>11313</org_study_id>
    <secondary_id>H9P-MC-LNBI</secondary_id>
    <nct_id>NCT00795821</nct_id>
  </id_info>
  <brief_title>A Study in Adult Patients With Major Depressive Disorder</brief_title>
  <official_title>A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment With LY2216684 in Adult Patients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether LY2216684 is superior to placebo in the
      treatment of adult patients with major depressive disorder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) at Week 10</measure>
    <time_frame>Baseline, Week 10</time_frame>
    <description>The MADRS measured severity of depressive mood symptoms. The 10-item checklist rating scale was 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline (Week 10) in Montgomery-Asberg Depression Rating Scale (MADRS) at Week 62</measure>
    <time_frame>Baseline (Week 10), Week 62</time_frame>
    <description>The MADRS measured severity of depressive mood symptoms. The 10-item checklist rating scale was 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Sheehan Disability Scale (SDS) Global Functional Impairment at Week 10</measure>
    <time_frame>Baseline, Week 10</time_frame>
    <description>The SDS was completed by the participant and used to assess the effect of the participant's symptoms on their work/social/family life. Total of these 3 items=Global Functional Impairment score; scores ranged from 0 to 30, with higher values indicating greater disruption in the participant's work/social/family life. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline (Week 10) in Sheehan Disability Scale (SDS) Global Functional Impairment at Week 62</measure>
    <time_frame>Baseline (Week 10), Week 62</time_frame>
    <description>The SDS was completed by the participant and used to assess the effect of the participant's symptoms on their work/social/family life. Total of these 3 items=Global Functional Impairment score; scores ranged from 0 to 30, with higher values indicating greater disruption in the participant's work/social/family life. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 10</measure>
    <time_frame>Baseline, Week 10</time_frame>
    <description>CGI-S measured severity of depression at the time of assessment. Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline (Week 10) in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 62</measure>
    <time_frame>Baseline (Week 10), Week 62</time_frame>
    <description>CGI-S measured severity of depression at the time of assessment. Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least Squares (LS) Means were adjusted for investigator, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the 16-Item Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-SR16) at Week 10</measure>
    <time_frame>Baseline, Week 10</time_frame>
    <description>The QIDS-SR16 was a 16-item participant-rated measure of depressive symptomatology. The total score ranged from 0 to 27, with higher scores indicative of greater severity. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline (Week 10) in the 16-Item Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-SR16) at Week 62</measure>
    <time_frame>Baseline (Week 10), Week 62</time_frame>
    <description>The QIDS-SR16 was a 16-item participant-rated measure of depressive symptomatology. The total score ranged from 0 to 27, with higher scores indicative of greater severity. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) at Week 10</measure>
    <time_frame>Baseline, Week 10</time_frame>
    <description>The CPFQ was a 7-item participant-rated questionnaire pertaining to a participant's cognitive and physical well-being. It assessed motivation, wakefulness, energy, focus, recall, word-finding difficulty, and mental acuity. Each item was scored on a 6-point scale ranging from 1 (greater than normal) to 6 (totally absent); total score ranged from 7 to 42. Least Squares (LS) Means were adjusted for treatment, investigator, and baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline (Week 10) in the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) at Week 62</measure>
    <time_frame>Baseline (Week 10), Week 62</time_frame>
    <description>The CPFQ was a 7-item participant-rated questionnaire pertaining to a participant's cognitive and physical well-being. It assessed motivation, wakefulness, energy, focus, recall, word-finding difficulty, and mental acuity. Each item was scored on a 6-point scale ranging from 1 (greater than normal) to 6 (totally absent); total score ranged from 7 to 42. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the EuroQol Questionnaire-5 Dimension (EQ-5D) United States (US) Index Score at Week 10</measure>
    <time_frame>Baseline, Week 10</time_frame>
    <description>EQ-5D was a generic, multidimensional, health-related, quality of life (Qol) instrument allowing participants to rate their health state in 5 domains: mobility, self-care, usual activities, pain/discomfort, and mood. A single score between 1 and 3 was generated for each domain. For each participant, the outcome rating on the 5 domains was mapped to a single index through an algorithm. The index ranged between 0 and 1, with the higher score indicating a better health state perceived by the participant. Least Squares (LS) Means were adjusted for treatment, investigator, and baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline (Week 10) in the EuroQol Questionnaire-5 Dimension (EQ-5D) United States (US) Index Score at Week 62</measure>
    <time_frame>Baseline (Week 10), Week 62</time_frame>
    <description>EQ-5D was a generic, multidimensional, health-related, quality of life (Qol) instrument allowing participants to rate their health state in 5 domains: mobility, self-care, usual activities, pain/discomfort, mood. Single score between 1 and 3 was generated for each domain. For each participant, outcome rating on the 5 domains was mapped to a single index through an algorithm. The index ranged between 0 and 1, with higher score indicating a better health state perceived by the participant. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Average Score at Week 10</measure>
    <time_frame>Baseline, Week 10</time_frame>
    <description>The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much). Average Score=mean of Items 1-5, 7-12, 14, and 16. Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline (Week 10) in Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Average Score at Week 62</measure>
    <time_frame>Baseline (Week 10), Week 62</time_frame>
    <description>The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much). Average Score=mean of Items 1-5, 7-12, 14, and 16. Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Fatigue Experience Average Score at Week 10</measure>
    <time_frame>Baseline, Week 10</time_frame>
    <description>The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much). Fatigue Experience Average Score=mean of Items 1 to 5, and 7. Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline (Week 10) in Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Fatigue Experience Average Score at Week 62</measure>
    <time_frame>Baseline (Week 10), Week 62</time_frame>
    <description>The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much). Fatigue Experience Average Score=mean of Items 1-5, and 7. Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Fatigue Impact Average Score at Week 10</measure>
    <time_frame>Baseline, Week 10</time_frame>
    <description>The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much). Fatigue Impact Average Score=mean of Items 8-12, 14, and 16. Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline (Week 10) in Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Fatigue Impact Average Score at Week 62</measure>
    <time_frame>Baseline (Week 10), Week 62</time_frame>
    <description>The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much). Fatigue Impact Average Score=mean of Items 8-12, 14, and 16. Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Brief Fatigue Inventory (BFI) Global Total Score at Week 10</measure>
    <time_frame>Baseline, Week 10</time_frame>
    <description>The BFI was a participant-rated scale consisting of 9 items: 3 items assessed severity of fatigue at its &quot;worst,&quot; &quot;usual,&quot; and &quot;now&quot; during normal waking hours: 0=no fatigue to 10=fatigue as bad as you can imagine; 6 items assessed the degree to which fatigue has interfered with different aspects of the participant's life during the past 24 hours: 0=does not interfere to 10=completely interferes. The BFI Global Total Score was the mean of the 9 item scores and ranged from 0 to 10. Least Squares (LS) Means were adjusted for treatment, investigator, and baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline (Week 10) in Brief Fatigue Inventory (BFI) Global Total Score at Week 62</measure>
    <time_frame>Baseline (Week 10), Week 62</time_frame>
    <description>The BFI was a participant-rated scale consisting of 9 items: 3 items assessed severity of fatigue at its &quot;worst,&quot; &quot;usual,&quot; and &quot;now&quot; during normal waking hours: 0=no fatigue to 10=fatigue as bad as you can imagine; 6 items assessed the degree to which fatigue has interfered with different aspects of the participant's life during the past 24 hours: 0=does not interfere to 10=completely interferes. The BFI Global Total Score was the mean of the 9 item scores and ranged from 0 to 10. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Visual Analogue Scale for Fatigue (VAS-F) Overall Severity and Interference With Daily Activities Scores at Week 10</measure>
    <time_frame>Baseline, Week 10</time_frame>
    <description>The VAS-F was a self-rated assessment with 2 items. For the Overall Severity of Fatigue item, the participant placed a vertical mark on a 100-millimeter (mm) line between 2 anchors (0=not at all to 100=as severe as I can imagine). For the Interference With Daily Activities Due to Fatigue item, the participant placed a vertical mark on a 100 mm line between 2 anchors (0=not at all to 100=complete disability [unable to do any activities]). Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline (Week 10) in the Visual Analogue Scale for Fatigue (VAS-F) Overall Severity and Interference With Daily Activities Scores at Week 62</measure>
    <time_frame>Baseline (Week 10), Week 62</time_frame>
    <description>The VAS-F was a self-rated assessment with 2 items. For the Overall Severity of Fatigue item, the participant placed a vertical mark on a 100-millimeter (mm) line between 2 anchors (0=not at all to 100=as severe as I can imagine). For the Interference With Daily Activities Due to Fatigue item, the participant placed a vertical mark on a 100 mm line between 2 anchors (0=not at all to 100=complete disability [unable to do any activities]). Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Resource Utilization at Week 10</measure>
    <time_frame>Baseline through Week 10</time_frame>
    <description>The Resource Utilization form assessed the frequency and type of medical services that participants have used within the last year, or since the last visit. Resources reported by at least 5% of participants in either treatment group were provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Resource Utilization at Week 62</measure>
    <time_frame>Baseline (Week 10) through Week 62</time_frame>
    <description>The Resource Utilization form assessed the frequency and type of medical services that participants have used within the last year, or since the last visit. Resources reported by at least 5% of participants in either treatment group were provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Suicidal Ideation, Behavior, and Acts Based on The Columbia Suicide Severity Rating Scale (C-SSRS) at Week 10</measure>
    <time_frame>Baseline through Week 10</time_frame>
    <description>C-SSRS scale captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Number of participants with suicidal ideation, behavior, and acts were provided. Suicidal ideation=a &quot;yes&quot; answer to any 1 of 5 suicidal ideation questions (including wish to be dead) and 4 different categories of active suicidal ideation. Suicidal behavior=a &quot;yes&quot; answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal act=a &quot;yes&quot; answer to actual attempt or completed suicide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Suicidal Ideation, Behavior, and Acts Based on The Columbia Suicide Severity Rating Scale (C-SSRS) at Week 62</measure>
    <time_frame>Baseline (Week 10) through Week 62</time_frame>
    <description>C-SSRS scale captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Number of participants with suicidal ideation, behavior, and acts were provided. Suicidal ideation=a &quot;yes&quot; answer to any 1 of 5 suicidal ideation questions (including wish to be dead) and 4 different categories of active suicidal ideation. Suicidal behavior=a &quot;yes&quot; answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal act=a &quot;yes&quot; answer to actual attempt or completed suicide.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Supine Systolic and Diastolic Blood Pressure at Week 10</measure>
    <time_frame>Baseline, Week 10</time_frame>
    <description>Blood pressure was collected while the participant was in the supine position. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline (Week 10) in Supine Systolic and Diastolic Blood Pressure at Week 62</measure>
    <time_frame>Baseline (Week 10), Week 62</time_frame>
    <description>Blood pressure was collected while the participant was in the supine position. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Supine Pulse at Week 10</measure>
    <time_frame>Baseline, Week 10</time_frame>
    <description>Pulse was collected while the participant was in the supine position. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline (Week 10) in Supine Pulse at Week 62</measure>
    <time_frame>Baseline (Week 10), Week 62</time_frame>
    <description>Pulse was collected while the participant was in the supine position. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: Plasma Concentration of LY2216684</measure>
    <time_frame>Baseline through Week 62</time_frame>
    <description>Blood samples collected from participants that received LY2216684 were measured to determine the plasma LY2216684 concentrations.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">495</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>LY2216684</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10-week Acute Treatment Phase: Day after Week 0=start of 6 milligram (mg) once daily (QD) dosing; Week 1=all participants titrated to 9 mg QD; After Week 1=dose increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.
1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of acute treatment phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10-week Acute Treatment Phase: 3 tablets QD for 10 weeks
1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684 dose; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2216684</intervention_name>
    <description>Flexible Dosing: 6 mg, 9 mg, 12 mg and 18 mg (3 tablets) administered QD for up to 62 weeks</description>
    <arm_group_label>LY2216684</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dose: 3 tablets QD for 10 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults age 18-65 years

          -  Meet criteria for major depressive disorder (MDD) as defined by Diagnostic and
             Statistical Manual of Mental Disorders-fourth edition-text revision (DSM-IV-TR)
             criteria without psychotic features

          -  Women of child-bearing potential must test negative for pregnancy and agree to use a
             reliable method of birth control

          -  Grid 17-item Hamilton Rating Scale for Depression (GRID-HAMD17) total score ≥18 at
             Visit 1 and Visit 2

          -  Clinical global impressions of severity (CGI-S) score ≥4 at Visit 1 and Visit 2

        Exclusion Criteria:

          -  Are currently involved in or discontinued within the last 30 days from a clinical
             trial involving an off-label use of an investigational drug

          -  Have previously completed or withdrawn from this study or any other study
             investigating LY2216684

          -  Have had or currently have any additional ongoing DSM-IV-TR Axis 1 condition other
             than MDD

          -  Have had any anxiety disorder preceding the onset of depression that was considered
             the primary diagnosis within 1 year of Visit 1

          -  Have an Axis II disorder that would interfere with protocol compliance

          -  Have a current or previous diagnosis of Bipolar I or II, psychotic depression,
             schizophrenia, or other psychotic disorder

          -  Have a history of substance abuse within the past 1 year

          -  Women who are pregnant or breast-feeding

          -  Have had a lack of response of the current depressive episode to 2 or more adequate
             courses of antidepressant therapy, or in the judgment of the investigator, considered
             to have treatment-resistant depression

          -  Participants who are judged to be at serious suicidal risk

          -  Have a serious or unstable medical illness

          -  Have any diagnosed medical condition which could be exacerbated by noradrenergic
             agents including unstable hypertension, unstable heart disease, tachycardia or
             tachyarrhythmia, narrow angle glaucoma, or urinary hesitation or retention

          -  Have received treatment with a monoamine oxidase inhibitor (MAOI) within 14 days prior
             to Visit 1

          -  Have a history of severe allergies to more than 1 class of medication or multiple
             adverse drug reactions

          -  Have a history of electroconvulsive therapy (ECT), transcranial magnetic stimulation
             (TMS) or psychosurgery within the last year

          -  Have a history of any seizure disorder (other than febrile seizures)

          -  Require psychotropic medication other than sedative/hypnotic medication for sleep

          -  Have a thyroid stimulating hormone (TSH) level outside the established reference
             range.

          -  Are taking or have received treatment with any excluded medication within 7 days prior
             to Visit 2

          -  Initiation or change in intensity of psychotherapy or other non-drug therapies within
             6 weeks prior to enrollment

          -  A positive urine drug screen for any substance of abuse at Visit 1

          -  Have initiated or discontinued hormone therapy within the previous 3 months prior to
             enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Smyrna</city>
        <state>Georgia</state>
        <zip>30080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Willingboro</city>
        <state>New Jersey</state>
        <zip>08046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425AHQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Plata</city>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Helsinki</city>
        <zip>00530</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oulu</city>
        <zip>90100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Belchatow</city>
        <zip>97-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bialystok</city>
        <zip>18-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gdansk</city>
        <zip>80 282</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gorlice</city>
        <zip>38-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leszno</city>
        <zip>64-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lublin</city>
        <zip>20-015</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tuszyn</city>
        <zip>95-080</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rostov-On-Don</city>
        <zip>344010</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191025</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tomsk</city>
        <zip>634014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Finland</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2008</study_first_submitted>
  <study_first_submitted_qc>November 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <results_first_submitted>February 17, 2018</results_first_submitted>
  <results_first_submitted_qc>March 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 20, 2018</results_first_posted>
  <disposition_first_submitted>January 28, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>January 28, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 7, 2011</disposition_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylethyl Alcohol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The Screening Phase (Week -1 through Week 0) assessed participant eligibility for not less than 3 days and not more than 30 days. At Week 0, those participants who met entry criteria were randomized in a 1:1 ratio to either LY2216684 (dose range 6 milligram [mg] to 18 mg once daily [QD]) or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LY2216684</title>
          <description>10-week Acute Treatment Phase: Day after Week 0=start of 6 milligram (mg) once daily (QD) dosing; Week 1=all participants titrated to 9 mg QD; After Week 1=dose increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.
1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of Acute Treatment Phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>10-week Acute Treatment Phase: 3 tablets QD for 10 weeks
1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Acute Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="250"/>
                <participants group_id="P2" count="245"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="194">4 LY-treated participants in the Acute Phase chose not to enter the Long-term Extension Phase.</participants>
                <participants group_id="P2" count="214">7 placebo-treated participants in the Acute Phase chose not to enter the Long-term Extension Phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long-term Extension Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="190"/>
                <participants group_id="P2" count="207">All placebo-treated participants received LY2216684 in the Long-term Extension Phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Taper Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="240">N=240 participants entered Taper Phases: N=4 from Acute Phase; N=236 from Extension Phase.</participants>
                <participants group_id="P2" count="6">N=6 participants entered only Acute Taper Phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="231">N=231 participants completed Taper Phases: N=3 from Acute Phase; N=228 from Extension Phase.</participants>
                <participants group_id="P2" count="6">N=6 participants completed only Acute Taper Phase; N=0 participants entered Extension Taper Phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LY2216684</title>
          <description>10-week Acute Treatment Phase: Day after Week 0=start of 6 milligram (mg) once daily (QD) dosing; Week 1=all participants titrated to 9 mg QD; After Week 1=dose increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.
1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of Acute Treatment Phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>10-week Acute Treatment Phase: 3 tablets QD for 10 weeks
1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="250"/>
            <count group_id="B2" value="245"/>
            <count group_id="B3" value="495"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.2" spread="11.32"/>
                    <measurement group_id="B2" value="45.5" spread="11.61"/>
                    <measurement group_id="B3" value="44.8" spread="11.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="303"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="400"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="187"/>
                    <measurement group_id="B3" value="378"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) at Week 10</title>
        <description>The MADRS measured severity of depressive mood symptoms. The 10-item checklist rating scale was 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline, Week 10</time_frame>
        <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684</title>
            <description>10-week Acute Treatment Phase: Day after Week 0=start of 6 mg QD dosing; Week 1=all participants were titrated to 9 mg QD; After Week 1=dose was increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>10-week Acute Treatment Phase: 3 tablets QD for 10 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) at Week 10</title>
          <description>The MADRS measured severity of depressive mood symptoms. The 10-item checklist rating scale was 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.30" spread="0.563"/>
                    <measurement group_id="O2" value="-9.82" spread="0.544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model terms included treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline (Week 10) in Montgomery-Asberg Depression Rating Scale (MADRS) at Week 62</title>
        <description>The MADRS measured severity of depressive mood symptoms. The 10-item checklist rating scale was 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline (Week 10), Week 62</time_frame>
        <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of Acute Treatment Phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
          <group group_id="O2">
            <title>Placebo/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline (Week 10) in Montgomery-Asberg Depression Rating Scale (MADRS) at Week 62</title>
          <description>The MADRS measured severity of depressive mood symptoms. The 10-item checklist rating scale was 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.44" spread="0.674"/>
                    <measurement group_id="O2" value="-9.43" spread="0.666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Sheehan Disability Scale (SDS) Global Functional Impairment at Week 10</title>
        <description>The SDS was completed by the participant and used to assess the effect of the participant's symptoms on their work/social/family life. Total of these 3 items=Global Functional Impairment score; scores ranged from 0 to 30, with higher values indicating greater disruption in the participant's work/social/family life. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline, Week 10</time_frame>
        <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684</title>
            <description>10-week Acute Treatment Phase: Day after Week 0=start of 6 mg QD dosing; Week 1=all participants were titrated to 9 mg QD; After Week 1=dose was increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>10-week Acute Treatment Phase: 3 tablets QD for 10 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Sheehan Disability Scale (SDS) Global Functional Impairment at Week 10</title>
          <description>The SDS was completed by the participant and used to assess the effect of the participant's symptoms on their work/social/family life. Total of these 3 items=Global Functional Impairment score; scores ranged from 0 to 30, with higher values indicating greater disruption in the participant's work/social/family life. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.21" spread="0.499"/>
                    <measurement group_id="O2" value="-5.79" spread="0.484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>To control for multiple comparisons, the analysis of this secondary outcome measure was pre-specified as a gated secondary objective. As the primary hypothesis was statistically significant, this hypothesis was tested at the 0.05 significance level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Model terms included treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline (Week 10) in Sheehan Disability Scale (SDS) Global Functional Impairment at Week 62</title>
        <description>The SDS was completed by the participant and used to assess the effect of the participant's symptoms on their work/social/family life. Total of these 3 items=Global Functional Impairment score; scores ranged from 0 to 30, with higher values indicating greater disruption in the participant's work/social/family life. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline (Week 10), Week 62</time_frame>
        <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of Acute Treatment Phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
          <group group_id="O2">
            <title>Placebo/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline (Week 10) in Sheehan Disability Scale (SDS) Global Functional Impairment at Week 62</title>
          <description>The SDS was completed by the participant and used to assess the effect of the participant's symptoms on their work/social/family life. Total of these 3 items=Global Functional Impairment score; scores ranged from 0 to 30, with higher values indicating greater disruption in the participant's work/social/family life. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.06" spread="0.654"/>
                    <measurement group_id="O2" value="-4.56" spread="0.591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 10</title>
        <description>CGI-S measured severity of depression at the time of assessment. Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline, Week 10</time_frame>
        <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684</title>
            <description>10-week Acute Treatment Phase: Day after Week 0=start of 6 mg QD dosing; Week 1=all participants were titrated to 9 mg QD; After Week 1=dose was increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>10-week Acute Treatment Phase: 3 tablets QD for 10 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 10</title>
          <description>CGI-S measured severity of depression at the time of assessment. Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="0.075"/>
                    <measurement group_id="O2" value="-1.08" spread="0.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model terms included treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline (Week 10) in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 62</title>
        <description>CGI-S measured severity of depression at the time of assessment. Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least Squares (LS) Means were adjusted for investigator, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline (Week 10), Week 62</time_frame>
        <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of Acute Treatment Phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
          <group group_id="O2">
            <title>Placebo/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline (Week 10) in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 62</title>
          <description>CGI-S measured severity of depression at the time of assessment. Scores ranged from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least Squares (LS) Means were adjusted for investigator, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" spread="0.087"/>
                    <measurement group_id="O2" value="-1.24" spread="0.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the 16-Item Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-SR16) at Week 10</title>
        <description>The QIDS-SR16 was a 16-item participant-rated measure of depressive symptomatology. The total score ranged from 0 to 27, with higher scores indicative of greater severity. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline, Week 10</time_frame>
        <population>The analysis population included all participants with a baseline and at least 1 post-baseline value in the Per Protocol population, defined as the subset of randomized participants who had baseline and post-baseline data collected using the correct version of the QIDS-SR16 worksheet.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684</title>
            <description>10-week Acute Treatment Phase: Day after Week 0=start of 6 mg QD dosing; Week 1=all participants were titrated to 9 mg QD; After Week 1=dose was increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>10-week Acute Treatment Phase: 3 tablets QD for 10 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the 16-Item Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-SR16) at Week 10</title>
          <description>The QIDS-SR16 was a 16-item participant-rated measure of depressive symptomatology. The total score ranged from 0 to 27, with higher scores indicative of greater severity. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all participants with a baseline and at least 1 post-baseline value in the Per Protocol population, defined as the subset of randomized participants who had baseline and post-baseline data collected using the correct version of the QIDS-SR16 worksheet.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.50" spread="0.366"/>
                    <measurement group_id="O2" value="-4.93" spread="0.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model terms included treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline (Week 10) in the 16-Item Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-SR16) at Week 62</title>
        <description>The QIDS-SR16 was a 16-item participant-rated measure of depressive symptomatology. The total score ranged from 0 to 27, with higher scores indicative of greater severity. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline (Week 10), Week 62</time_frame>
        <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of Acute Treatment Phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
          <group group_id="O2">
            <title>Placebo/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684 dose; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline (Week 10) in the 16-Item Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-SR16) at Week 62</title>
          <description>The QIDS-SR16 was a 16-item participant-rated measure of depressive symptomatology. The total score ranged from 0 to 27, with higher scores indicative of greater severity. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.64" spread="0.422"/>
                    <measurement group_id="O2" value="-3.33" spread="0.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) at Week 10</title>
        <description>The CPFQ was a 7-item participant-rated questionnaire pertaining to a participant's cognitive and physical well-being. It assessed motivation, wakefulness, energy, focus, recall, word-finding difficulty, and mental acuity. Each item was scored on a 6-point scale ranging from 1 (greater than normal) to 6 (totally absent); total score ranged from 7 to 42. Least Squares (LS) Means were adjusted for treatment, investigator, and baseline score.</description>
        <time_frame>Baseline, Week 10</time_frame>
        <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684</title>
            <description>10-week Acute Treatment Phase: Day after Week 0=start of 6 mg QD dosing; Week 1=all participants were titrated to 9 mg QD; After Week 1=dose was increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>10-week Acute Treatment Phase: 3 tablets QD for 10 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) at Week 10</title>
          <description>The CPFQ was a 7-item participant-rated questionnaire pertaining to a participant's cognitive and physical well-being. It assessed motivation, wakefulness, energy, focus, recall, word-finding difficulty, and mental acuity. Each item was scored on a 6-point scale ranging from 1 (greater than normal) to 6 (totally absent); total score ranged from 7 to 42. Least Squares (LS) Means were adjusted for treatment, investigator, and baseline score.</description>
          <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.61" spread="0.435"/>
                    <measurement group_id="O2" value="-5.04" spread="0.437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms included treatment, investigator, and baseline score.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline (Week 10) in the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) at Week 62</title>
        <description>The CPFQ was a 7-item participant-rated questionnaire pertaining to a participant's cognitive and physical well-being. It assessed motivation, wakefulness, energy, focus, recall, word-finding difficulty, and mental acuity. Each item was scored on a 6-point scale ranging from 1 (greater than normal) to 6 (totally absent); total score ranged from 7 to 42. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline (Week 10), Week 62</time_frame>
        <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of Acute Treatment Phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
          <group group_id="O2">
            <title>Placebo/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline (Week 10) in the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ) at Week 62</title>
          <description>The CPFQ was a 7-item participant-rated questionnaire pertaining to a participant's cognitive and physical well-being. It assessed motivation, wakefulness, energy, focus, recall, word-finding difficulty, and mental acuity. Each item was scored on a 6-point scale ranging from 1 (greater than normal) to 6 (totally absent); total score ranged from 7 to 42. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.79" spread="0.534"/>
                    <measurement group_id="O2" value="-3.72" spread="0.480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the EuroQol Questionnaire-5 Dimension (EQ-5D) United States (US) Index Score at Week 10</title>
        <description>EQ-5D was a generic, multidimensional, health-related, quality of life (Qol) instrument allowing participants to rate their health state in 5 domains: mobility, self-care, usual activities, pain/discomfort, and mood. A single score between 1 and 3 was generated for each domain. For each participant, the outcome rating on the 5 domains was mapped to a single index through an algorithm. The index ranged between 0 and 1, with the higher score indicating a better health state perceived by the participant. Least Squares (LS) Means were adjusted for treatment, investigator, and baseline score.</description>
        <time_frame>Baseline, Week 10</time_frame>
        <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684</title>
            <description>10-week Acute Treatment Phase: Day after Week 0=start of 6 mg QD dosing; Week 1=all participants were titrated to 9 mg QD; After Week 1=dose was increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>10-week Acute Treatment Phase: 3 tablets QD for 10 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the EuroQol Questionnaire-5 Dimension (EQ-5D) United States (US) Index Score at Week 10</title>
          <description>EQ-5D was a generic, multidimensional, health-related, quality of life (Qol) instrument allowing participants to rate their health state in 5 domains: mobility, self-care, usual activities, pain/discomfort, and mood. A single score between 1 and 3 was generated for each domain. For each participant, the outcome rating on the 5 domains was mapped to a single index through an algorithm. The index ranged between 0 and 1, with the higher score indicating a better health state perceived by the participant. Least Squares (LS) Means were adjusted for treatment, investigator, and baseline score.</description>
          <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.011"/>
                    <measurement group_id="O2" value="0.09" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms included treatment, investigator, and baseline score.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline (Week 10) in the EuroQol Questionnaire-5 Dimension (EQ-5D) United States (US) Index Score at Week 62</title>
        <description>EQ-5D was a generic, multidimensional, health-related, quality of life (Qol) instrument allowing participants to rate their health state in 5 domains: mobility, self-care, usual activities, pain/discomfort, mood. Single score between 1 and 3 was generated for each domain. For each participant, outcome rating on the 5 domains was mapped to a single index through an algorithm. The index ranged between 0 and 1, with higher score indicating a better health state perceived by the participant. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline (Week 10), Week 62</time_frame>
        <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of Acute Treatment Phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
          <group group_id="O2">
            <title>Placebo/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline (Week 10) in the EuroQol Questionnaire-5 Dimension (EQ-5D) United States (US) Index Score at Week 62</title>
          <description>EQ-5D was a generic, multidimensional, health-related, quality of life (Qol) instrument allowing participants to rate their health state in 5 domains: mobility, self-care, usual activities, pain/discomfort, mood. Single score between 1 and 3 was generated for each domain. For each participant, outcome rating on the 5 domains was mapped to a single index through an algorithm. The index ranged between 0 and 1, with higher score indicating a better health state perceived by the participant. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.015"/>
                    <measurement group_id="O2" value="0.06" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Average Score at Week 10</title>
        <description>The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much). Average Score=mean of Items 1-5, 7-12, 14, and 16. Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline, Week 10</time_frame>
        <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684</title>
            <description>10-week Acute Treatment Phase: Day after Week 0=start of 6 mg QD dosing; Week 1=all participants were titrated to 9 mg QD; After Week 1=dose was increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>10-week Acute Treatment Phase: 3 tablets QD for 10 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Average Score at Week 10</title>
          <description>The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much). Average Score=mean of Items 1-5, 7-12, 14, and 16. Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.99" spread="0.059"/>
                    <measurement group_id="O2" value="-0.74" spread="0.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model terms included treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline (Week 10) in Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Average Score at Week 62</title>
        <description>The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much). Average Score=mean of Items 1-5, 7-12, 14, and 16. Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline (Week 10), Week 62</time_frame>
        <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of Acute Treatment Phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
          <group group_id="O2">
            <title>Placebo/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline (Week 10) in Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Average Score at Week 62</title>
          <description>The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much). Average Score=mean of Items 1-5, 7-12, 14, and 16. Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.076"/>
                    <measurement group_id="O2" value="-0.65" spread="0.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Fatigue Experience Average Score at Week 10</title>
        <description>The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much). Fatigue Experience Average Score=mean of Items 1 to 5, and 7. Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline, Week 10</time_frame>
        <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684</title>
            <description>10-week Acute Treatment Phase: Day after Week 0=start of 6 mg QD dosing; Week 1=all participants were titrated to 9 mg QD; After Week 1=dose was increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>10-week Acute Treatment Phase: 3 tablets QD for 10 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Fatigue Experience Average Score at Week 10</title>
          <description>The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much). Fatigue Experience Average Score=mean of Items 1 to 5, and 7. Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="0.060"/>
                    <measurement group_id="O2" value="-0.69" spread="0.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model terms included treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline (Week 10) in Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Fatigue Experience Average Score at Week 62</title>
        <description>The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much). Fatigue Experience Average Score=mean of Items 1-5, and 7. Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline (Week 10), Week 62</time_frame>
        <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of Acute Treatment Phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
          <group group_id="O2">
            <title>Placebo/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline (Week 10) in Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Fatigue Experience Average Score at Week 62</title>
          <description>The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much). Fatigue Experience Average Score=mean of Items 1-5, and 7. Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.080"/>
                    <measurement group_id="O2" value="-0.70" spread="0.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Fatigue Impact Average Score at Week 10</title>
        <description>The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much). Fatigue Impact Average Score=mean of Items 8-12, 14, and 16. Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline, Week 10</time_frame>
        <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684</title>
            <description>10-week Acute Treatment Phase: Day after Week 0=start of 6 mg QD dosing; Week 1=all participants were titrated to 9 mg QD; After Week 1=dose was increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>10-week Acute Treatment Phase: 3 tablets QD for 10 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Fatigue Impact Average Score at Week 10</title>
          <description>The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much). Fatigue Impact Average Score=mean of Items 8-12, 14, and 16. Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" spread="0.062"/>
                    <measurement group_id="O2" value="-0.77" spread="0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model terms included treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline (Week 10) in Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Fatigue Impact Average Score at Week 62</title>
        <description>The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much). Fatigue Impact Average Score=mean of Items 8-12, 14, and 16. Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline (Week 10), Week 62</time_frame>
        <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of Acute Treatment Phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline (Week 10) in Fatigue Associated With Depression (FAsD) Patient Reported Outcome (PRO): Fatigue Impact Average Score at Week 62</title>
          <description>The FAsD was a participant-rated scale with 7 items that asked how often they experience different aspects of fatigue: responses from 1 (Never) to 5 (Always); 9 items that asked how often fatigue impacts various aspects of their lives: responses from 1 (Not at all) to 5 (Very much). Fatigue Impact Average Score=mean of Items 8-12, 14, and 16. Scores ranged from 1 to 5. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.078"/>
                    <measurement group_id="O2" value="-0.58" spread="0.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Brief Fatigue Inventory (BFI) Global Total Score at Week 10</title>
        <description>The BFI was a participant-rated scale consisting of 9 items: 3 items assessed severity of fatigue at its “worst,” “usual,” and “now” during normal waking hours: 0=no fatigue to 10=fatigue as bad as you can imagine; 6 items assessed the degree to which fatigue has interfered with different aspects of the participant’s life during the past 24 hours: 0=does not interfere to 10=completely interferes. The BFI Global Total Score was the mean of the 9 item scores and ranged from 0 to 10. Least Squares (LS) Means were adjusted for treatment, investigator, and baseline score.</description>
        <time_frame>Baseline, Week 10</time_frame>
        <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684</title>
            <description>10-week Acute Treatment Phase: Day after Week 0=start of 6 mg QD dosing; Week 1=all participants were titrated to 9 mg QD; After Week 1=dose was increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>10-week Acute Treatment Phase: 3 tablets QD for 10 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Brief Fatigue Inventory (BFI) Global Total Score at Week 10</title>
          <description>The BFI was a participant-rated scale consisting of 9 items: 3 items assessed severity of fatigue at its “worst,” “usual,” and “now” during normal waking hours: 0=no fatigue to 10=fatigue as bad as you can imagine; 6 items assessed the degree to which fatigue has interfered with different aspects of the participant’s life during the past 24 hours: 0=does not interfere to 10=completely interferes. The BFI Global Total Score was the mean of the 9 item scores and ranged from 0 to 10. Least Squares (LS) Means were adjusted for treatment, investigator, and baseline score.</description>
          <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.25" spread="0.147"/>
                    <measurement group_id="O2" value="-1.74" spread="0.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>ANCOVA</method>
            <method_desc>Model terms included treatment, investigator, and baseline score.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline (Week 10) in Brief Fatigue Inventory (BFI) Global Total Score at Week 62</title>
        <description>The BFI was a participant-rated scale consisting of 9 items: 3 items assessed severity of fatigue at its “worst,” “usual,” and “now” during normal waking hours: 0=no fatigue to 10=fatigue as bad as you can imagine; 6 items assessed the degree to which fatigue has interfered with different aspects of the participant’s life during the past 24 hours: 0=does not interfere to 10=completely interferes. The BFI Global Total Score was the mean of the 9 item scores and ranged from 0 to 10. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline (Week 10), Week 62</time_frame>
        <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of Acute Treatment Phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
          <group group_id="O2">
            <title>Placebo/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline (Week 10) in Brief Fatigue Inventory (BFI) Global Total Score at Week 62</title>
          <description>The BFI was a participant-rated scale consisting of 9 items: 3 items assessed severity of fatigue at its “worst,” “usual,” and “now” during normal waking hours: 0=no fatigue to 10=fatigue as bad as you can imagine; 6 items assessed the degree to which fatigue has interfered with different aspects of the participant’s life during the past 24 hours: 0=does not interfere to 10=completely interferes. The BFI Global Total Score was the mean of the 9 item scores and ranged from 0 to 10. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="0.202"/>
                    <measurement group_id="O2" value="-1.59" spread="0.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Visual Analogue Scale for Fatigue (VAS-F) Overall Severity and Interference With Daily Activities Scores at Week 10</title>
        <description>The VAS-F was a self-rated assessment with 2 items. For the Overall Severity of Fatigue item, the participant placed a vertical mark on a 100-millimeter (mm) line between 2 anchors (0=not at all to 100=as severe as I can imagine). For the Interference With Daily Activities Due to Fatigue item, the participant placed a vertical mark on a 100 mm line between 2 anchors (0=not at all to 100=complete disability [unable to do any activities]). Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline, Week 10</time_frame>
        <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684</title>
            <description>10-week Acute Treatment Phase: Day after Week 0=start of 6 mg QD dosing; Week 1=all participants were titrated to 9 mg QD; After Week 1=dose was increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>10-week Acute Treatment Phase: 3 tablets QD for 10 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Visual Analogue Scale for Fatigue (VAS-F) Overall Severity and Interference With Daily Activities Scores at Week 10</title>
          <description>The VAS-F was a self-rated assessment with 2 items. For the Overall Severity of Fatigue item, the participant placed a vertical mark on a 100-millimeter (mm) line between 2 anchors (0=not at all to 100=as severe as I can imagine). For the Interference With Daily Activities Due to Fatigue item, the participant placed a vertical mark on a 100 mm line between 2 anchors (0=not at all to 100=complete disability [unable to do any activities]). Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severity of Overall Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.30" spread="1.813"/>
                    <measurement group_id="O2" value="-16.69" spread="1.757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue Interference With Daily Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.48" spread="1.831"/>
                    <measurement group_id="O2" value="-18.62" spread="1.775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>P-value for Severity of Overall Fatigue</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Model terms included treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <p_value_desc>P-value for Fatigue Interference with Daily Activities</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Model terms included treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline (Week 10) in the Visual Analogue Scale for Fatigue (VAS-F) Overall Severity and Interference With Daily Activities Scores at Week 62</title>
        <description>The VAS-F was a self-rated assessment with 2 items. For the Overall Severity of Fatigue item, the participant placed a vertical mark on a 100-millimeter (mm) line between 2 anchors (0=not at all to 100=as severe as I can imagine). For the Interference With Daily Activities Due to Fatigue item, the participant placed a vertical mark on a 100 mm line between 2 anchors (0=not at all to 100=complete disability [unable to do any activities]). Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline (Week 10), Week 62</time_frame>
        <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of Acute Treatment Phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
          <group group_id="O2">
            <title>Placebo/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline (Week 10) in the Visual Analogue Scale for Fatigue (VAS-F) Overall Severity and Interference With Daily Activities Scores at Week 62</title>
          <description>The VAS-F was a self-rated assessment with 2 items. For the Overall Severity of Fatigue item, the participant placed a vertical mark on a 100-millimeter (mm) line between 2 anchors (0=not at all to 100=as severe as I can imagine). For the Interference With Daily Activities Due to Fatigue item, the participant placed a vertical mark on a 100 mm line between 2 anchors (0=not at all to 100=complete disability [unable to do any activities]). Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Severity of Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.72" spread="2.277"/>
                    <measurement group_id="O2" value="-18.69" spread="1.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue Interference With Daily Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.89" spread="2.229"/>
                    <measurement group_id="O2" value="-17.47" spread="1.996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Resource Utilization at Week 10</title>
        <description>The Resource Utilization form assessed the frequency and type of medical services that participants have used within the last year, or since the last visit. Resources reported by at least 5% of participants in either treatment group were provided.</description>
        <time_frame>Baseline through Week 10</time_frame>
        <population>The analysis population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684</title>
            <description>10-week Acute Treatment Phase: Day after Week 0=start of 6 mg QD dosing; Week 1=all participants were titrated to 9 mg QD; After Week 1=dose was increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>10-week Acute Treatment Phase: 3 tablets QD for 10 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Resource Utilization at Week 10</title>
          <description>The Resource Utilization form assessed the frequency and type of medical services that participants have used within the last year, or since the last visit. Resources reported by at least 5% of participants in either treatment group were provided.</description>
          <population>The analysis population included all randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Use of Primary Doctor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of Specialist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Diagnostic Tests</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prescribed Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1"/>
                    <measurement group_id="O2" value="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.261</p_value>
            <p_value_desc>P-value for participants reporting use of primary doctor</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel (CMH) test controlling for investigator.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.868</p_value>
            <p_value_desc>P-value for participants reporting use of specialist</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel (CMH) test controlling for investigator.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.495</p_value>
            <p_value_desc>P-value for participants reporting other diagnostic tests</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel (CMH) test controlling for investigator.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.189</p_value>
            <p_value_desc>P-value for participants reporting prescribed medication</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel (CMH) test controlling for investigator.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Resource Utilization at Week 62</title>
        <description>The Resource Utilization form assessed the frequency and type of medical services that participants have used within the last year, or since the last visit. Resources reported by at least 5% of participants in either treatment group were provided.</description>
        <time_frame>Baseline (Week 10) through Week 62</time_frame>
        <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of Acute Treatment Phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
          <group group_id="O2">
            <title>Placebo/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Resource Utilization at Week 62</title>
          <description>The Resource Utilization form assessed the frequency and type of medical services that participants have used within the last year, or since the last visit. Resources reported by at least 5% of participants in either treatment group were provided.</description>
          <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Use of Primary Doctor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3"/>
                    <measurement group_id="O2" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of Specialist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0"/>
                    <measurement group_id="O2" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of ER or Urgent Care: Other Reason</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Special Scans/Tests</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2"/>
                    <measurement group_id="O2" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Diagnostic Tests</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2"/>
                    <measurement group_id="O2" value="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prescribed Medications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5"/>
                    <measurement group_id="O2" value="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Suicidal Ideation, Behavior, and Acts Based on The Columbia Suicide Severity Rating Scale (C-SSRS) at Week 10</title>
        <description>C-SSRS scale captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Number of participants with suicidal ideation, behavior, and acts were provided. Suicidal ideation=a &quot;yes&quot; answer to any 1 of 5 suicidal ideation questions (including wish to be dead) and 4 different categories of active suicidal ideation. Suicidal behavior=a &quot;yes&quot; answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal act=a &quot;yes&quot; answer to actual attempt or completed suicide.</description>
        <time_frame>Baseline through Week 10</time_frame>
        <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline C-SSRS value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684</title>
            <description>10-week Acute Treatment Phase: Day after Week 0=start of 6 mg QD dosing; Week 1=all participants were titrated to 9 mg QD; After Week 1=dose was increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>10-week Acute Treatment Phase: 3 tablets QD for 10 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Suicidal Ideation, Behavior, and Acts Based on The Columbia Suicide Severity Rating Scale (C-SSRS) at Week 10</title>
          <description>C-SSRS scale captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Number of participants with suicidal ideation, behavior, and acts were provided. Suicidal ideation=a &quot;yes&quot; answer to any 1 of 5 suicidal ideation questions (including wish to be dead) and 4 different categories of active suicidal ideation. Suicidal behavior=a &quot;yes&quot; answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal act=a &quot;yes&quot; answer to actual attempt or completed suicide.</description>
          <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline C-SSRS value.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Suicidal ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                    <measurement group_id="O2" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal acts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.737</p_value>
            <p_value_desc>P-value for suicidal ideation</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Suicidal Ideation, Behavior, and Acts Based on The Columbia Suicide Severity Rating Scale (C-SSRS) at Week 62</title>
        <description>C-SSRS scale captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Number of participants with suicidal ideation, behavior, and acts were provided. Suicidal ideation=a &quot;yes&quot; answer to any 1 of 5 suicidal ideation questions (including wish to be dead) and 4 different categories of active suicidal ideation. Suicidal behavior=a &quot;yes&quot; answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal act=a &quot;yes&quot; answer to actual attempt or completed suicide.</description>
        <time_frame>Baseline (Week 10) through Week 62</time_frame>
        <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of Acute Treatment Phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
          <group group_id="O2">
            <title>Placebo/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Suicidal Ideation, Behavior, and Acts Based on The Columbia Suicide Severity Rating Scale (C-SSRS) at Week 62</title>
          <description>C-SSRS scale captured occurrence, severity, and frequency of suicide-related thoughts and behaviors. Number of participants with suicidal ideation, behavior, and acts were provided. Suicidal ideation=a &quot;yes&quot; answer to any 1 of 5 suicidal ideation questions (including wish to be dead) and 4 different categories of active suicidal ideation. Suicidal behavior=a &quot;yes&quot; answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal act=a &quot;yes&quot; answer to actual attempt or completed suicide.</description>
          <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Suicidal ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal acts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Supine Systolic and Diastolic Blood Pressure at Week 10</title>
        <description>Blood pressure was collected while the participant was in the supine position. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline, Week 10</time_frame>
        <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684</title>
            <description>10-week Acute Treatment Phase: Day after Week 0=start of 6 mg QD dosing; Week 1=all participants were titrated to 9 mg QD; After Week 1=dose was increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>10-week Acute Treatment Phase: 3 tablets QD for 10 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Supine Systolic and Diastolic Blood Pressure at Week 10</title>
          <description>Blood pressure was collected while the participant was in the supine position. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
          <units>millimeters of mercury (mm Hg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Supine systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="0.708"/>
                    <measurement group_id="O2" value="-1.57" spread="0.683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.54" spread="0.527"/>
                    <measurement group_id="O2" value="-0.64" spread="0.510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P-value for change in supine systolic blood pressure</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Model terms included treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for change in supine diastolic blood pressure</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Model terms included treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline (Week 10) in Supine Systolic and Diastolic Blood Pressure at Week 62</title>
        <description>Blood pressure was collected while the participant was in the supine position. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline (Week 10), Week 62</time_frame>
        <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of Acute Treatment Phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
          <group group_id="O2">
            <title>Placebo/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline (Week 10) in Supine Systolic and Diastolic Blood Pressure at Week 62</title>
          <description>Blood pressure was collected while the participant was in the supine position. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
          <units>millimeters of mercury (mm Hg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Supine systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="1.017"/>
                    <measurement group_id="O2" value="2.55" spread="1.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.724"/>
                    <measurement group_id="O2" value="2.25" spread="0.710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Supine Pulse at Week 10</title>
        <description>Pulse was collected while the participant was in the supine position. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline, Week 10</time_frame>
        <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684</title>
            <description>10-week Acute Treatment Phase: Day after Week 0=start of 6 mg QD dosing; Week 1=all participants were titrated to 9 mg QD; After Week 1=dose was increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>10-week Acute Treatment Phase: 3 tablets QD for 10 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Supine Pulse at Week 10</title>
          <description>Pulse was collected while the participant was in the supine position. Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all randomized participants with a baseline and at least 1 post-baseline value.</population>
          <units>beats per minute (bpm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.72" spread="0.677"/>
                    <measurement group_id="O2" value="-0.11" spread="0.655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Model terms included treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline (Week 10) in Supine Pulse at Week 62</title>
        <description>Pulse was collected while the participant was in the supine position. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
        <time_frame>Baseline (Week 10), Week 62</time_frame>
        <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of Acute Treatment Phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
          <group group_id="O2">
            <title>Placebo/LY2216684</title>
            <description>1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline (Week 10) in Supine Pulse at Week 62</title>
          <description>Pulse was collected while the participant was in the supine position. Least Squares (LS) Means were adjusted for investigator, visit, baseline score, and baseline-by-visit.</description>
          <population>The analysis population included all participants in the Long-term Extension Phase with a baseline and at least 1 post-baseline value.</population>
          <units>beats per minute (bpm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" spread="0.970"/>
                    <measurement group_id="O2" value="7.33" spread="0.875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK) Parameter: Plasma Concentration of LY2216684</title>
        <description>Blood samples collected from participants that received LY2216684 were measured to determine the plasma LY2216684 concentrations.</description>
        <time_frame>Baseline through Week 62</time_frame>
        <population>N=number of participants analyzed (N=365); n=number of plasma LY2216684 concentration observations. The sum of the individual ‘n’ values for each dose group does not equal 365 since the same participant could have received various doses during his/her participation in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2216684</title>
            <description>10-week Acute Treatment Phase: Day after Week 0=start of 6 mg QD dosing; Week 1=all participants were titrated to 9 mg QD; After Week 1=dose was increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.
1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of acute treatment phase, or 6 mg LY2216684 dose if participants were taking placebo; After Week 1=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Parameter: Plasma Concentration of LY2216684</title>
          <description>Blood samples collected from participants that received LY2216684 were measured to determine the plasma LY2216684 concentrations.</description>
          <population>N=number of participants analyzed (N=365); n=number of plasma LY2216684 concentration observations. The sum of the individual ‘n’ values for each dose group does not equal 365 since the same participant could have received various doses during his/her participation in the study.</population>
          <units>nanograms per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="365"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 mg LY2216684</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="8.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 mg LY2216684</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="328"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 mg LY2216684</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 mg LY2216684</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" spread="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LY2216684 - Acute</title>
          <description>10-week Acute Treatment Phase: Day after Week 0=start of 6 milligram (mg) once daily (QD) dosing; Week 1=all participants titrated to 9 mg QD; After Week 1=dose increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.</description>
        </group>
        <group group_id="E2">
          <title>Placebo - Acute</title>
          <description>10-week Acute Treatment Phase: 3 tablets QD for 10 weeks</description>
        </group>
        <group group_id="E3">
          <title>LY2216684/LY2216684 - Extension</title>
          <description>1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of Acute Treatment Phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
        </group>
        <group group_id="E4">
          <title>Placebo/LY2216684 - Extension</title>
          <description>1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62).</description>
        </group>
        <group group_id="E5">
          <title>LY2216684 - Taper</title>
          <description>Participants who took 18 mg LY2216684 received 12 mg QD for 1 week followed by 6 mg QD for 1 week. Participants who took 12 mg, 9 mg, or 6 mg LY2216684 received 6 mg QD for 2 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Placebo - Taper</title>
          <description>Participants who took placebo remained on placebo for 2 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="190"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="207"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ruptured cerebral aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="250"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="126" subjects_at_risk="190"/>
                <counts group_id="E4" subjects_affected="155" subjects_at_risk="207"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="240"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Macrocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aortic valve sclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cardiac flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Left atrial dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="250"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="250"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="190"/>
                <counts group_id="E4" events="21" subjects_affected="17" subjects_at_risk="207"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="190"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="250"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bowel movement irregularity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="250"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="190"/>
                <counts group_id="E4" events="13" subjects_affected="12" subjects_at_risk="207"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="245"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="250"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="190"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="190"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="40" subjects_affected="39" subjects_at_risk="250"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="245"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="190"/>
                <counts group_id="E4" events="29" subjects_affected="23" subjects_at_risk="207"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="250"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="190"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Device leakage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="250"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="207"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Feeling drunk</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Feeling jittery</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Feeling of body temperature change</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hunger</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="250"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="245"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sluggishness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="190"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Chlamydial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="250"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="190"/>
                <counts group_id="E4" events="18" subjects_affected="18" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="250"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="250"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="190"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Drug exposure during pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Spinal cord injury sacral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bleeding time prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood pressure diastolic decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood pressure diastolic increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="250"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="190"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood pressure orthostatic decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood pressure orthostatic increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Heart rate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="250"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="190"/>
                <counts group_id="E4" events="14" subjects_affected="13" subjects_at_risk="207"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tuberculin test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="250"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vitamin B12 deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="190"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Joint crepitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neck mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="190"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tenosynovitis stenosans</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Complex regional pain syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="250"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="190"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness exertional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Drug withdrawal headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Head titubation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="37" subjects_affected="27" subjects_at_risk="250"/>
                <counts group_id="E2" events="28" subjects_affected="22" subjects_at_risk="245"/>
                <counts group_id="E3" events="21" subjects_affected="16" subjects_at_risk="190"/>
                <counts group_id="E4" events="32" subjects_affected="27" subjects_at_risk="207"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypogeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypokinesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="190"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Parosmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="250"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="190"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anorgasmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="190"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Binge eating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Blunted affect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Bruxism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dissociation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Emotional disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="250"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="190"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Loss of libido</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Middle insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nicotine dependence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Orgasm abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Orgasmic sensation decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Terminal insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tobacco withdrawal symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary hesitation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="190"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urine flow decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexa uteri pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ejaculation disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Ejaculation failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nipple disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oligomenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Penile pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Penis disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Scrotal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oropharyngeal blistering</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Yawning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="250"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="190"/>
                <counts group_id="E4" events="37" subjects_affected="28" subjects_at_risk="207"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia facial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Piloerection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Skin warm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Ex-tobacco user</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Angiopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="250"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="250"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="250"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="190"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Poor peripheral circulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vasoconstriction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

